SABCS 2023 | The emerging role of AKT inhibitors in breast cancer

Cynthia Ma, MD, PhD, Washington University, St. Louis, MO, provides an overview of current AKT inhibitors for breast cancer. Capivasertib, which was assessed in the Phase III CAPItello-291 trial (NCT04305496), was recently approved by the FDA for breast cancer. In the trial, patients who were pre-treated with prior CDK4/6 inhibition had improved survival rates when taking capivasertib. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.